A Phase II Study of the BRAF Inhibitor Vemurafenib Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

  • STATUS
    Recruiting
  • End date
    Jan 11, 2022
  • participants needed
    30
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 11 February 2021
BRAF

Summary

This is a multi-center, open label, single arm, phase II trial of the oral BRAF inhibitor, vemurafenib, plus obinutuzumab in patients with previously untreated HCL. A Simon mini-max two-stage design will be employed to assess the efficacy of the combination treatment of vemurafenib and obinutuzumab. In the first stage of the protocol, 9 patients will be treated. If fewer than 6 CRs are seen among the first 9 patients, the study will be closed for lack of efficacy. If at least 7 patients respond to the treatment, then an additional 19 patients will be accrued to the second stage, for a total of 28 patients.

Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment. After the completion of the treatment (i.e. after 4 cycles), a bone marrow aspirate and biopsy will be performed for assessment of response and evaluation of minimal residual disease (MRD). In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.

Details
Condition Hairy Cell Leukemia, leukemia, Leukemia (Pediatric), leukemias
Treatment Obinutuzumab, Vemurafenib
Clinical Study IdentifierNCT03410875
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on11 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Hairy Cell Leukemia or Leukemia (Pediatric) or leukemia?
Do you have any of these conditions: leukemia or Leukemia (Pediatric) or Hairy Cell Leukemia or leukemias?
Do you have any of these conditions: Leukemia (Pediatric) or Hairy Cell Leukemia or leukemia or leukemias?
Do you have any of these conditions: leukemias or Leukemia (Pediatric) or leukemia or Hairy Cell Leukemia?
Do you have any of these conditions: leukemia or leukemias or Hairy Cell Leukemia or Leukemia (Pediatric)?
Patients must be >/= 18 years of age
Histologically confirmed classical HCL by the enrolling institution
Has not received any prior therapy for the disease
Patients who meet the standard treatment initiation criteria, as defined by ANC </=1.0, Hgb </=10.0 or PLT </=100K
ECOG performance status of 0-2
Acceptable pre-study organ function during screening as defined as
Total bilirubin </= 1.5 times the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </=2.5x ULN
Serum creatinine </=1.5x ULN
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QT Bazett's formula) of <480 msec
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
Negative serum pregnancy test with 7 days of commencement of treatment in women of childbearing potential

Exclusion Criteria

Have had previous treatment for HCL, including purine analogs, rituximab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed
Known hypersensitivity to any of the study drugs
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Patients with uncorrectable electrolyte abnormalities with potassium (K) >ULN (upper limit of normal)
Patients with any active and uncontrolled infections (such as bacterial, fungal, and new or reactivated viral infections)
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
Invasive malignancy that require active systemic chemotherapy or biologics that may cause significant drug-drug interaction with either vemurafenib or obinutuzumab
Malabsorption syndrome or other condition that precludes enteral route of administration
Patients with HCL variant (as defined by absence of expression of CD25)
Pregnant or lactating, or intending to become pregnant during the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note